(Q38194611)

English

Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis

scientific article published on 11 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

0 references

1 reference

Europe PubMed Central

Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

30 August 2017

Helicobacter pylori

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shu-Ping Xiao

1

1 reference

Europe PubMed Central

30 August 2017

Min Gu

2

1 reference

Europe PubMed Central

30 August 2017

Guo-Xin Zhang

3

1 reference

Europe PubMed Central

30 August 2017

publication date

11 March 2014

1 reference

Europe PubMed Central

30 August 2017

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

30 August 2017

49

1 reference

Europe PubMed Central

30 August 2017

5

1 reference

Europe PubMed Central

30 August 2017

528-538

1 reference

Europe PubMed Central

30 August 2017

Host-bacterial interactions in Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Carcinogenesis of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Helicobacter pyloriInfection

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Treatment of Helicobacter pylori infection 2011.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

A new look at anti-Helicobacter pylori therapy

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Helicobacter pylori therapy demystified

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

"Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

H pylori antibiotic resistance: prevalence, importance, and advances in testing

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Factors associated with treatment failure of Helicobacter pylori infection in a developing country

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.887765

21 January 2018

Identifiers

10.3109/00365521.2014.887765

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38194611&oldid=1746489418"